Search

everythinglearnresearchcommunity

for

Search:↓

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.

An 18-year-old man was diagnosed with a rare genetic disorder causing hair loss, severe light sensitivity, and skin issues.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.

Tofacitinib is a promising treatment for children with rheumatic diseases.

AIMP1 can boost hair growth by increasing stem cell activity.

Oral isotretinoína effectively stabilizes frontal fibrosing alopecia.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Finasteride may cause cataracts and floppy-iris syndrome.

Finasteride may help treat frontal fibrosing alopecia, but more research is needed.

Thermal imaging is a useful non-invasive method to diagnose active inflammation in frontal fibrosing alopecia.

5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.

Tofacitinib helped a woman regrow hair with no major side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.